IP Verse

(+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione: Methods Of Using And Compositions Thereof - EP2223688

The patent EP2223688 was granted to Amgen Europe on May 29, 2019. The application was originally filed on Mar 20, 2003 under application number EP10162667A. The patent is currently recorded with a legal status of "Revoked".

EP2223688

AMGEN EUROPE
Application Number
EP10162667A
Filing Date
Mar 20, 2003
Status
Revoked
Jan 21, 2022
Publication Date
May 29, 2019
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (5)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

GALENICUM HEALTH SLUMar 2, 2020-ADMISSIBLE
HEXALFeb 28, 2020TER MEER STEINMEISTER & PARTNERADMISSIBLE
HOFFMANN EITLEFeb 28, 2020-ADMISSIBLE
ZENTIVA KSFeb 28, 2020HOFFMANN EITLEADMISSIBLE
WUESTHOFF & WUESTHOFF PATENTANWALTE PARTG MBBFeb 26, 2020SONNENHAUSERADMISSIBLE

Patent Citations (21) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONUS3536809
DESCRIPTIONUS3598123
DESCRIPTIONUS3845770
DESCRIPTIONUS3916899
DESCRIPTIONUS4008719
DESCRIPTIONUS5059595
DESCRIPTIONUS5073543
DESCRIPTIONUS5120548
DESCRIPTIONUS5354556
DESCRIPTIONUS5591767
DESCRIPTIONUS5639476
DESCRIPTIONUS5674533
DESCRIPTIONUS5733566
DESCRIPTIONUS6020358
OPPOSITIONEP1485087
OPPOSITIONEP1752148
OPPOSITIONUS366515
OPPOSITIONUS6020358
OPPOSITIONUS6025347
OPPOSITIONWO0025777
SEARCHUS6020358

Non-Patent Literature (NPL) Citations (64) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
DESCRIPTION- AU ET AL., BRIT. J. PHARM., (1998), vol. 123, pages 1260 - 1266
DESCRIPTION- BAEHR ET AL., J. BIOL. CHEM., (1979), vol. 254, page 11669
DESCRIPTION- BAUGHMAN ET AL., J. LAB. CLIN. MED., (1990), vol. 115, pages 36 - 42
DESCRIPTION- BEAVO; REITSNYDER, TRENDS IN PHARM., (1990), vol. 11, pages 150 - 155
DESCRIPTION- BERTOLINI ET AL., NATURE, (1986), vol. 319, pages 516 - 518
DESCRIPTION- BISSONNETTE ET AL., INFLAMMATION, (1989), vol. 13, pages 329 - 339
DESCRIPTION- BLOOM; BEAVO, PROC. NATL. ACAD SCI. USA, (1996), vol. 93, pages 14188 - 14192
DESCRIPTION- CLOUSE ET AL., J. IMMUNOL., (1989), vol. 142, pages 431 - 438
DESCRIPTION- CORRAL ET AL., MOL. MED, (1996), vol. 2, pages 506 - 515
DESCRIPTION- DERIAN ET AL., J IMMUNOL., (1995), vol. 154, pages 308 - 317
DESCRIPTION- DERIAN ET AL., J. IMMUNOL., (1995), vol. 154, pages 308 - 3 17
DESCRIPTION- DEZUBE ET AL., LANCET, (1990), vol. 335, page 662
DESCRIPTION- DUB ET AL., PROC. NAT. ACAD. SCI., (1989), vol. 86, pages 5974 - 5978
DESCRIPTION- ELLIOT ET AL., INT. J. PHARMAC., (1995), vol. 17, pages 141 - 145
DESCRIPTION- FERRAI-BALIVIERA ET AL., ARCH. SURG., (1989), vol. 124, pages 1400 - 1405
DESCRIPTION- FOLKS ET AL., PNAS, (1989), vol. 86, pages 2365 - 2368
DESCRIPTION- GEORGE MULLER ET AL., BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, (1999), vol. 9, pages 1625 - 1630
DESCRIPTION- GILLESPIE ET AL., MOL. PHARM., (1989), vol. 36, page 773
DESCRIPTION- GRAU ET AL., N. ENGL. J. MED., (1989), vol. 320, pages 1586 - 1591
DESCRIPTION- HATZELMANN; SCHUDT, J. PHARM. EXP. THER., (2001), vol. 297, pages 267 - 279
DESCRIPTION- HIDAKA; ASANO, BIOCHEM. BIOPHYS. ACTA, (1976), vol. 429, page 485
DESCRIPTION- HINSHAW ET AL., CIRC. SHOCK, (1990), vol. 30, pages 279 - 292
DESCRIPTION- HOLLER, BLOOD, (1990), vol. 75, pages 1011 - 1016
DESCRIPTION- JOHNSON ET AL., ENDOCRINOLOGY, (1989), vol. 124, pages 1424 - 1427
DESCRIPTION- LIST ET AL., J. CLIN. ONCOL., (1990), vol. 8, page 1424
DESCRIPTION- LOWE; CHENG, DRUGS OF THE FUTURE, (1992), vol. 17, no. 9, pages 799 - 807
DESCRIPTION- LOWE, EXP. OPIN. THER. PATENTS, (1998), vol. 8, pages 1309 - 1332
DESCRIPTION- MILLAR ET AL., LANCET, (1989), vol. 2, pages 712 - 714
DESCRIPTION- MONTO ET AL., BLOOD, (1990), vol. 79, page 2670
DESCRIPTION- MULLER ET AL., BIOORG. & MED CHEM LETT, (1998), vol. 8, pages 2669 - 2674
DESCRIPTION- MULLER ET AL., J MED CHEM., (1996), vol. 39, page 3238
DESCRIPTION- NICHOLSEN ET AL., TRENDS PHARMACO. SCI., (1991), vol. 12, page 19
DESCRIPTION- PIGNET ET AL., NATURE, (1990), vol. 344, pages 245 - 247
DESCRIPTION- POLI ET AL., PROC. NATL. ACAD. SCI., (1990), vol. 87, pages 782 - 784
DESCRIPTION- POLL ET AL., AIDS RES. HUM. RETROVIRUS, (1992), pages 191 - 197
DESCRIPTION- POLL ET AL., PROC. NAT. ACAD. SCI., (1990), vol. 87, pages 782 - 785
DESCRIPTION- RICE, SCIENCE, (1989), vol. 246, pages 1303 - 1306
DESCRIPTION- TRACEY, NATURE, (1987), vol. 330, pages 662 - 664
DESCRIPTION- VERGHESE ET AL., JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, (1995), vol. 272, no. 3, pages 1313 - 1320
DESCRIPTION- VON DULLEMEN ET AL., GASTROENTEROLOGY, (1995), vol. 109, pages 129 - 135
DESCRIPTION- WILEN, S. H. ET AL., TETRAHEDRON, (1977), vol. 33, page 2725
OPPOSITION- Anonymous, "Development of New stereoisomeric drugs", FDA Guideline, (19920501), pages 1 - 7, FDA Guideline, (20191125), XP055645997
OPPOSITION- Anonymus, "Apremilast", Wikipedia, (20170508), XP055697439
OPPOSITION- ARIËNS et al., "Stereochemistry, a Basis for Sophisticated Nonsense in Pharmacokinetics and Clinical Pharmacology", Eur. J. Clin. Pharmacol., (19840000), vol. 26, pages 663 - 668, XP055646360
OPPOSITION- Bibiana Bielekova, Nancy Richert, Thomas Howard Et Al.,, "Treatment with the phosphodiesterase type-4 inhibitor rolipram fails to inhibit blood-brain barrier disruption in multiple sclerosis /Abstract/", Multiple Sclerosis Journal, Multiple Sclerosis Journal, URL: http://journals.sagepub.com/doi/pdf/10.1177/1352458509345903, (20180411), XP055466489
OPPOSITION- DYKE H J, MONTANA J G, "UPDATE ON THE THERAPEUTIC POTENTIAL OF PDE4 INHIBITORS", Expert Opinion on Investigational Drugs, Informa Healthcare, UK, UK, (20020101), vol. 01, no. 11, ISSN 1354-3784, pages 01 - 13, XP008002007
OPPOSITION- Eduardo Fernandez-Martinez, "In: ISBN 978-1-61209-248-5 Editor: Thalidomide and its Analogs: A Potential Immunomodulatory Alternative for Treating Liver Diseases and Cirrhosis", Liver Cirrhosis: Causes, Diagnosis and Treatment, (20110101), pages 1 - 29, Liver Cirrhosis: Causes, Diagnosis and Treatment, URL: https://pdfs.semanticscholar.org/2f8d/9fde7cee9454f19f0424b7c7fb1f43872a65.pdf?_ga=2.93293269.970082538.1591620233-977581868.1591620233, (20200608), XP055702359
OPPOSITION- GENOVESE MC et al., Apremilast in patients with active rheumatoid arthritis: A phase II, multicentre, randomized, double-blind, placebo-controlled, parallel-group study, (20150000), XP055466494
OPPOSITION- Hanns-Martin Lorenz, Et Al, "Supplement Review Perspectives for TNF-α-targeting therapies", Arthritis Research, (20020101), vol. 4, no. 3, pages 17 - 24, XP055702353
OPPOSITION- Jean Jacques, Et Al, "Dissociable compounds and complexes", Enantiomers, racemates and Resolutions, Wiley, (19810101), pages 251 - 261, XP055702332
OPPOSITION- J. W. Nieuwenhuijzen, "Resolutions with families of resolving agents: principles and practice", Thesis, (20020101), pages 24 - 46, Thesis, (20191209), XP055650625
OPPOSITION- Mark C. Genovese, Et Al.,, "Apremilast in Patients With Active Rheumatoid Arthritis: A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study /Abstract/", Wiley Online Library, Wiley Online Library, URL: https://onlinelibrary.wiley.com/doi/full/10.1002/art.39120, (20180411), XP055466494
OPPOSITION- Nancy Walsh, "Otezla Disappoints in RA - Efficacy of apremilast in rheumatoid arthritis no different from placebo", MEDPAGE TODAY, (20150325), MEDPAGE TODAY, URL: https://www.medpagetoday.com/rheumatology/arthritis/50659, (20180411), XP055466491
OPPOSITION- Nancy Walsh, "Otezla Disappoints in RA - Efficacy of apremilast in rheumatoid arthritis no different from placebo", MEDPAGE TODAY, MEDPAGE TODAY, URL: https://www.medpagetoday.com/rheumatology/arthritis/50659, (20180411), XP055466491
OPPOSITION- Newman, "section 4", Optical Resolution Procedures for chemical compounds, (19840101), pages 1 - 3,583-590, XP055646345
OPPOSITION- Samuel H Wilen, "Tables of resolving agents and optical resolutions", Tables of resolving agents and optical resolutions, (19720101), pages 24,25,142 - 143, XP055702338
OPPOSITION- SOUNESS JE et al., "Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNFa generation from human monocysts by interacting with a 'low- affinity' phosphodiesterase 4 conformer", British Journal of Pharmacology, (19960000), vol. 118, pages 649 - 658, XP055650622
OPPOSITION- BERTIL WALDECK, "Biological Significance of Enantiomeric Purity of Drugs", CHIRALITY, (19930000), vol. 5, doi:10.1002/chir.530050514, pages 350 - 355, XP055406849
OPPOSITION- WILLIAMS, "Enantiomers in Arthritic Disorders", Pharmac. Ther., (19900000), vol. 46, doi:10.1016/0163-7258(90)90095-J, pages 273 - 295, XP023850665
OPPOSITION- MULLER et al., "Amino- Substituted Thalidomide Analogs: Potent Inhibitors of TNF-a Production", Bioorg. Med. Chem. Lett., (19990000), vol. 9, doi:10.1016/S0960-894X(99)00250-4, pages 1625 - 1630, XP004169632
OPPOSITION- KLEINMAN et al., "Striking Effect of Hydroxamic Acid Substitution on the Phosphodiesterase Type 4 (PDE4) and TNFa", J. Med. Chem., (19980000), vol. 41, doi:10.1021/jm970685m, pages 266 - 270, XP002093975
OPPOSITION- SOUNESS et al., "Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNFa generation from human monocytes by interacting with a ''low-affinity'' phosphodiesterase 4 conformer", British J. Pharmacol., (19960000), vol. 118, doi:10.1111/j.1476-5381.1996.tb15450.x, pages 649 - 658, XP055406854
OPPOSITION- KELLER et al., "Synthesis and Structure- Activity Relationship of N-Arylrolipram Derivatives as Inhibitors of PDE4 Isozymes", Chem. Pharm Bull., (20010000), vol. 49, doi:10.1248/cpb.49.1009, pages 1009 - 1017, XP055645955
OPPOSITION- DYKE H J, MONTANA J G, "THE THERAPEUTIC POTENTIAL OF PDE4 INHIBITORS", Expert Opinion on Investigational Drugs, Informa Healthcare, UK, UK, (19990101), vol. 08, no. 09, doi:10.1517/13543784.8.9.1301, ISSN 1354-3784, pages 1301 - 1325, XP001096074

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents